Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
Free ArticleExplore Premium Services
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
One of these mRNA pioneers has the products and pipeline to drive growth.
By Adria Cimino -- Nov 20, 2026 at 3:55AM EST +Fool.comon
Key Points
Both companies are working to move beyond their coronavirus vaccine windfalls.
These biotech players aim to make strides in cancer treatment.
The coronavirus pandemic turned two little-known mRNA companies into household names. Moderna (MRNA +1.29%) and BioNTech (BNTX -2.26%) brought their vaccines to market, collected billions of dollars in revenue, and then watched demand fade in recent years. Both stocks fell significantly from their highs, and both companies have spent the past few years trying to prove they're more than coronavirus vaccine makers.
This year, their paths have diverged. Moderna's stock has soared as investors rushed to bet on the company's promising personalized cancer vaccine program. BioNTech, meanwhile, saw its stock price slip and prepared to say goodbye to its founders.
So, heading into 2027, which of these mRNA pioneers is the better buy?
Image source: Getty Images.
Two companies, two different paths
First, a quick recap. Both companies have faced the same problem: the coronavirus vaccine was a windfall that couldn't last. Moderna's product sales peaked at more than $18 billion in 2022, and BioNTech's reached a high of about the same level in 2021. Each responded by cutting costs and shifting toward oncology. BioNTech has more than 25 phase 2 and phase 3 clinical trials ongoing in that treatment area. Moderna's personalized cancer vaccine candidate, intismeran autogene, is involved in four phase 3 trials and several earlier-stage trials.
BioNTech has real strengths. It has more than $17 billion in cash and investments, and its lead candidate, pumitamig, is a bispecific antibody it's developing with Bristol Myers Squibb. The company is evaluating pumitamig in seven global pivotal studies across several cancer types. Meanwhile, BioNTech recently had mixed results in a phase 3 trial of an antibody-drug conjugate with DualityBio. Though the candidate met its primary endpoint, its impact may be "limited," the companies said.
The coronavirus vaccine remains BioNTech's only commercialized product for the moment as we wait for the pipeline to potentially produce others. And the company will see its CEO, Uğur Şahin, and chief medical officer, Özlem Türeci, leave at year-end. A new CEO takes over by Feb. 1. That's a lot of change during a critical stretch.
-- Price
Moderna's products and pipeline
Moderna, by contrast, has several commercialized products. Third-quarter revenue rose 29% to $1.3 billion, and net income was $162 million, a big swing from a loss a year earlier. Management raised its 2026 revenue growth outlook to a range of 15% to 25%, up from an earlier forecast of up to 10%. The biotech company now has five approved products, including a flu vaccine approved in the U.S. this year. A limited launch has already delivered more than 110,000 vaccinations, and Moderna is preparing a broader rollout for the 2027-2028 respiratory season.
The bigger prize is oncology, and in a phase 3 melanoma trial, intismeran plus Merck's Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone. Intismeran is also in studies for lung, bladder, and kidney cancers, so melanoma could be just the first of several revenue streams.
Catalysts ahead in 2027
Next year offers several potential catalysts. Moderna and Merck said they'd be in contact with regulators about filing for intismeran approval, so investors should watch for submission news. Moderna will also provide formal 2027 financial guidance with its fourth-quarter report, and it's still awaiting FDA guidance on refiling its flu and COVID combination vaccine. Finally, in Europe, Moderna expects an opportunity to gain share as a competitor's COVID-19 vaccine contract expires.
Moderna isn't risk-free. The company still must gain regulatory approval for intismeran and prove the candidate's strength in several other clinical trials, and the stock's huge run raises expectations. Investors may see volatility around 2027 guidance.
BioNTech has the cash and a promising pipeline, and it may reward patient investors down the road. But its biggest opportunities are further out, and it's navigating a leadership overhaul along the way. Moderna offers a rarer combination: growing sales today, a cancer therapy that could reach the market soon, and a broadening vaccine lineup. That's why Moderna is my pick between the two, to buy and hold for the long term. |
| Read Next |
|---|
| Nov 19, 2026 •By Rick Orford Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing. |
| Nov 16, 2026 •By David Jagielski, CPA Is Moderna's Cancer Vaccine a Game Changer for the Stock? |
| Nov 14, 2026 •By Brendan Coffey Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027? |
| Nov 12, 2026 •By Rich Smith Why Moderna Stock Dropped on Thursday |
| Nov 9, 2026 •By David Jagielski, CPA Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy |
| Nov 9, 2026 •By RJ Fulton BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027 |
| ### About the Author |
| Adria Cimino is a contributing Motley Fool stock market analyst covering healthcare, technology, and consumer goods sectors. Prior to The Motley Fool, Adria covered the European stock market and U.S. stocks pre-market trading for Bloomberg News, Bloomberg TV, and Bloomberg Radio for more than a decade. Earlier in her career, she wrote about biotech, medtech, and technology companies in Boston for Mass High Tech, an American City Business Journals publication. She holds a bachelor's degree in mass communications from the University of South Florida. |
| TMFAdriaCimino |
| X @adria_in_paris Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Bristol Myers Squibb, Merck, and Moderna. The Motley Fool has a disclosure policy. |
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

2 Financial Stocks to Buy Near Their 52-Week Lows

US Treasury sells $15 billion in first nine-day cash bill auction since 2008

Not Anthropic. Not SpaceX. This Is the AI Stock to Buy for the Long Term

Bitcoin Has Traded Below Its 200-Week Average Only 8.4% of the Time. History Says This Is When Patient Investors Get Paid.

Greg Abel Just Approved a Record $9.6 Billion in Stock Buybacks for Berkshire Hathaway Last Quarter, More Than Double the Pace Set in the Second Quarter. Is Berkshire Still a Buy as Shares Sit Near All-Time Highs?

Solana Heads Towards Its Worst Year in History

If AI Chips Become Commoditized, Nvidia Has the Most to Lose, While These 3 Stocks Are Set to Gain

3 Data Center Power Stocks Down More Than a Third From Their Records to Buy Now and Hold Through 2030

NFT sales rise to $33M as Ethereum trading jumps 33%

SBF Expresses Regret Over Anthropic Sale: AI Has a 25% Chance of Destroying Humanity, Young People Should Master AI

The S&P 500 Just Entered Correction Territory. Here's What It Means for Investors Right Now.

Is the Era of Easy Money in the Crypto Industry Over? Four Schemes That Drain Market Liquidity

Penetrating Social Trading Ledgers: Who is Really Making Profits Amidst the Traffic Noise?

Prediction: Rocket Lab Will Triple Its Revenue by 2028. Here's What That Would Mean for the Stock.

Is Coca-Cola a Millionaire-Maker Stock?

Just 2.5% of recent Bitcoin buyers’ exchange deposits were in profit

Securitize pays its first tokenized Apple stock dividend in USDC

SBF’s 'The Altruists' Plot Twist: FTX’s Anthropic Shares Would Be Worth $43 Billion

YETI and LBank Show How IP Collaborations Are Reshaping Crypto Marketing

Forget SpaceX: This Stock Could Be the Real Winner of the Space Race

If I Could Only Own 1 Trillion-Dollar Artificial Intelligence (AI) Stock Through 2030, It Would Be Anthropic, Nvidia, or Alphabet. Here's My Top Pick.

US Data Center Construction Costs Surge 13% in 2026

As traditional giants rush into digital dollars, USDD’s Yvonne Chia explains why 24/7 access, self-custody, and transparent yield give decentralized stablecoins an edge banks can’t replicate.

Walsh Wants Fed Officials to Speak Less, but Their Remarks Have Increased

The Nasdaq Is In Its Third Correction of 2026. Here's the Lesson Most Investors Are Missing.

Technical Failures Are Inevitable, But Business Chaos Can Be Avoided

Costco Just Made a New All-Time High After Announcing a $30-Per-Share Special Dividend. Is the Stock a Buy Before Dec. 10?

Ethereum Delays Update Amid Massive Cost Surge

Is Arthur Hayes buying the dip after moving $5M in USDC?










